Global Markets
Home›Global Markets›Europe›Shareholders sue Novo Nordisk over CagriSema tolerabil…
Shareholders sue Novo Nordisk over CagriSema tolerability claims
Investors allege Novo Nordisk misled the market about CagriSema’s tolerability, pointing to disappointing clinical trial results that cut the company’s market value by billions.
CNBC World reports that shareholders are suing Novo Nordisk, alleging the company misled investors about the tolerability of its next-generation obesity drug CagriSema.
The dispute centers on clinical trial outcomes that fell short, which shareholders say contributed to a major market reaction.
According to the report, disappointing results erased billions from Novo Nordisk’s market capitalization, fueling claims that earlier disclosures did not match the drug’s eventual tolerability profile.